Pontine Glioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018

  • ID: 4460749
  • Report
  • Region: Global
  • 100 Pages
  • VPA Research
1 of 4
This Research Analyzes the Evolution of Glioma Clinical Trial Trends Across Countries and Regions

Glioma clinical trials report provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Glioma clinical trials.

Major drugs under development in Glioma are provided in the report along with their details of Mechanism of action, route of administration, target, therapy, molecule and class.

Scope of the Report:

  • Number of Glioma clinical trials across regions - Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Glioma
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Glioma clinical trials worldwide are listed

Reasons to Buy:

  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market

Glioma - The condition occurs when the glial cells in the brain are affected and account for around one -third of all brain tumors. On the basis of location, these are classified as supratentorial (above tentorium) and infratentorial (below tenotrium).

On the basis of pace of development, these are categorized as Low grade (grades 1 and 2) and high grade (3 and 4). Treatment options vary with the grade of the disease, but most often it includes a combination of medicine, surgery, radiation and chemo therapies.

Malignant Glioma - Malignant Glioma is the most regular subtypes of glioma condition occurring in patients aged between 60 and 80. The condition is classified as grade 3 and grade 4, which comprises anaplastic high -grade gliomas and glioblastomas respectively.

High Grade Glioma - Malignant or high -grade glioma tumors are categorized as Grade 3 and Grade 4. Of this Grade 3 tumor types include -

Anaplastic astrocytoma - The rare disease type comprises an estimated one -third of all astrocytoma types. Often observed in older persons, the condition can occur in any aged person. Astrocytoma emerges from star shaped cells in the brain, called astrocytes.

Anaplastic oligodendroglioma - It is a rare type of malignant tumor occurring mainly between 45 and 50 years of age. They possess abnormal genetic material and unique molecular, clinical, and histological characteristics and are important to diagnose.

Anaplastic oligoastrocytoma - Oligoastrocytoma occurs when either oligodendrocytes and astrocytes or both grow rapidly, causing formation of tumors in the brain. The term ‘Anaplastic’ refers to condition when tumor can spread into nearby tissues. They occur in Cerebrum area.

Anaplastic ependymoma - The fast growing subtype occurs primarily in posterior fossa part. The tumor cells show rapid growth pace and are associated with a less favorable prognosis and have higher possibility to infiltrate around the brain or disseminate into cerebrospinal fluid resulting in drop metastases.

Glioblastoma - The grade 4 type condition is further classified as primary and secondary types. The primary subtype occurs without earlier diagnosis of low grade tumors while the secondary type arouses from development of grade 2 or 3 subtypes. Tumor occurs as a result of accumulation of different mutations.

Pontine Gliomas - Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of malignant glioma, arising from glioma tissue. As these are observed in the bottom area of the brain, they are tough to be treated. It is observed mostly in children.

Low Grade Glioma (LGGs) or often referred to as Grade - 1 and 2 tumors, arouse from brain cells including astrocytes and oligodendrocytes. Causing mild and large seizures, the Glioma type is treated through a combination of surgery, chemotherapy, and radiation on the basis of disease condition. The condition is primarily observed in young and healthy individuals. Compared to high grade Glioma, these patients survive for long periods and lead quality life as this is a slow growth disease.

On the basis of appearance under microscope and genetic modifications, Low grade gliomas are classified as -
Pilocytic astrocytomas - Observed in adults aging less than 25 and progresses very slowly compared to other types

Diffuse astrocytomas - Most observed subtype of low - grade glioma. Late 30’s individuals are the most affected age. Type of modification in IDH isocitrate -dehydrogenase gene determines the sub -types of Diffuse astrocytomas.

Oligodendrogliomas - Slow growing tumors, having mutation in the IDH gene in terms of missing 1p and 19q chromosomes.

Gangliogliomas - Posesses both gliomas and tumor related characteristics.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010 - 2017
2.2.3 Prominent Companies in Global Pontine Glioma Trials, 2010 - 2017

3 Pontine Glioma Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for Pontine Glioma
3.2 Pontine Glioma Product Snapshots
3.2.1 Pontine Glioma Drug Profiles

4 Global Pontine Glioma Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010 - 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010 - 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010 - 2017
4.4 Subjects Recruited by Region, 2010 - 2017
4.5 Clinical Trials by Year, 2010 - 2017
4.6 Subjects Recruited by Year, 2010 - 2017
4.7 Clinical Trials by Development Phase, 2010 - 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010 - 2017
4.9 Clinical Trials by Status, 2010 - 2017
4.10 Subjects Recruited by Trial Status, 2010 - 2017
4.11 Clinical Trials by Sponsor Type, 2010 - 2017
4.12 Subjects Recruited by Sponsor Type, 2010 - 2017
4.13 Clinical Trials by Economy Type, 2010 - 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010 - 2017

5 Europe Pontine Glioma Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Europe, 2010 - 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010 - 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010 - 2017
5.4 Europe, Clinical Trials by Development Phase, 2010 - 2017
5.5 Europe, Clinical Trials by Trial Status, 2010 - 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010 - 2017

6 North America Pontine Glioma Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in North America, 2010 - 2017
6.1.1 North America, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in North America, 2010 - 2017
6.2.1 North America, Total Enrolment by Country
6.3 North America, Clinical Trials by Year, 2010 - 2017
6.4 North America, Clinical Trials by Development Phase, 2010 - 2017
6.5 North America, Clinical Trials by Trial Status, 2010 - 2017
6.6 North America, Clinical Trials by Sponsor Type, 2010 - 2017

7 Western Pacific Pontine Glioma Clinical Trial Research Trends
7.1 Clinical Trials by Top Countries in Western Pacific, 2010 - 2017
7.1.1 Western Pacific, Clinical Trials by Country
7.2 Subjects Recruited by Top Countries in Western Pacific, 2010 - 2017
7.2.1 Western Pacific, Total Enrolment by Country
7.3 Western Pacific, Clinical Trials by Year, 2010 - 2017
7.4 Western Pacific, Clinical Trials by Development Phase, 2010 - 2017
7.5 Western Pacific, Clinical Trials by Trial Status, 2010 - 2017
7.6 Western Pacific, Clinical Trials by Sponsor Type, 2010 - 2017

8 Recent Clinical Trials - Snapshots
8.1 Pontine Glioma Trial Snapshots - 2018
8.2 Pontine Glioma Trial Snapshots - 2017
8.3 Pontine Glioma Trial Snapshots - 2016
8.4 Pontine Glioma Trial Snapshots - 2015
8.5 Pontine Glioma Trial Snapshots - 2014
8.6 Pontine Glioma Trial Snapshots - 2013
8.7 Pontine Glioma Trial Snapshots - 2012
8.8 Pontine Glioma Trial Snapshots - 2011
8.9 Pontine Glioma Trial Snapshots - 2010

9 Appendix
9.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Pontine Glioma - Average Enrolment by Country, 2010 - 2017
Figure 2: Pontine Glioma - Country wise Clinical Trials, 2010 - 2017
Figure 3: Pontine Glioma - Country wise Recruiting Sites, 2010 - 2017
Figure 4: Pontine Glioma - Country wise Subjects Recruited, 2010 - 2017
Figure 5: Global Pontine Glioma Clinical Trials Participation Share by Region, 2010 - 2017
Figure 6: Global Pontine Glioma Subjects Recruited by Region, 2010 - 2017
Figure 7: Global Pontine Glioma Clinical Trials by Year, 2010 - 2017
Figure 8: Global Pontine Glioma Subjects Recruited by Year, 2010 - 2017
Figure 9: Global Pontine Glioma Trials by Phase, 2010 - 2017
Figure 10: Global Pontine Glioma - Subjects Recruited by Phase, 2010 - 2017
Figure 11: Global Pontine Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 12: Global Pontine Glioma - Subjects Recruited by Trial Status, 2010 - 2017
Figure 13: Global Pontine Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 14: Global Pontine Glioma - Subjects Recruited by Trial Status, 2010 - 2017
Figure 15: Global Pontine Glioma - Clinical Trials by Type of Economy, 2010 - 2017
Figure 16: Europe Pontine Glioma - Country wise Clinical Trials, 2010 - 2017
Figure 17: Europe Pontine Glioma - Country wise Subjects Recruited, 2010 - 2017
Figure 18: Europe Pontine Glioma - Year wise Clinical Trials, 2010 - 2017
Figure 19: Europe Pontine Glioma Trials by Phase, 2010 - 2017
Figure 20: Europe Pontine Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 21: Europe Pontine Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 22: North America Pontine Glioma - Country wise Clinical Trials, 2010 - 2017
Figure 23: North America Pontine Glioma - Country wise Subjects Recruited, 2010 - 2017
Figure 24: North America Pontine Glioma - Year wise Clinical Trials, 2010 - 2017
Figure 25: North America Pontine Glioma Trials by Phase, 2010 - 2017
Figure 26: North America Pontine Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 27: North America Pontine Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 28: Western Pacific Pontine Glioma - Country wise Clinical Trials, 2010 - 2017
Figure 29: Western Pacific Pontine Glioma - Country wise Subjects Recruited, 2010 - 2017
Figure 30: Western Pacific Pontine Glioma - Year wise Clinical Trials, 2010 - 2017
Figure 31: Western Pacific Pontine Glioma Trials by Phase, 2010 - 2017
Figure 32: Western Pacific Pontine Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 33: Western Pacific Pontine Glioma - Clinical Trials by Sponsor Type, 2010 - 2017

1.2 List of Tables
Table 1: Pontine Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 2: Pontine Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 3: Pontine Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 4: Pontine Glioma - Region wise Clinical Trials, 2010 - 2017
Table 5: Pontine Glioma - Region wise Subjects Recruited, 2010 - 2017
Table 6: Global Pontine Glioma - Clinical Trials and Subjects by Trial Type, 2010 - 2017
Table 7: Pontine Glioma Trial Snapshots - 2018
Table 8: Pontine Glioma Trial Snapshots - 2017
Table 9: Pontine Glioma Trial Snapshots - 2017
Table 10: Pontine Glioma Trial Snapshots - 2017
Table 11: Pontine Glioma Trial Snapshots - 2017
Table 12: Pontine Glioma Trial Snapshots - 2017
Table 13: Pontine Glioma Trial Snapshots - 2017
Table 14: Pontine Glioma Trial Snapshots - 2017
Table 15: Pontine Glioma Trial Snapshots - 2016
Table 16: Pontine Glioma Trial Snapshots - 2016
Table 17: Pontine Glioma Trial Snapshots - 2016
Table 18: Pontine Glioma Trial Snapshots - 2016
Table 19: Pontine Glioma Trial Snapshots - 2016
Table 20: Pontine Glioma Trial Snapshots - 2016
Table 21: Pontine Glioma Trial Snapshots - 2016
Table 22: Pontine Glioma Trial Snapshots - 2016
Table 23: Pontine Glioma Trial Snapshots - 2016
Table 24: Pontine Glioma Trial Snapshots - 2016
Table 25: Pontine Glioma Trial Snapshots - 2015
Table 26: Pontine Glioma Trial Snapshots - 2015
Table 27: Pontine Glioma Trial Snapshots - 2015
Table 28: Pontine Glioma Trial Snapshots - 2015
Table 29: Pontine Glioma Trial Snapshots - 2015
Table 30: Pontine Glioma Trial Snapshots - 2015
Table 31: Pontine Glioma Trial Snapshots - 2014
Table 32: Pontine Glioma Trial Snapshots - 2014
Table 33: Pontine Glioma Trial Snapshots - 2014
Table 34: Pontine Glioma Trial Snapshots - 2014
Table 35: Pontine Glioma Trial Snapshots - 2013
Table 36: Pontine Glioma Trial Snapshots - 2013
Table 37: Pontine Glioma Trial Snapshots - 2013
Table 38: Pontine Glioma Trial Snapshots - 2013
Table 39: Pontine Glioma Trial Snapshots - 2012
Table 40: Pontine Glioma Trial Snapshots - 2012
Table 41: Pontine Glioma Trial Snapshots - 2011
Table 42: Pontine Glioma Trial Snapshots - 2011
Table 43: Pontine Glioma Trial Snapshots - 2011
Table 44: Pontine Glioma Trial Snapshots - 2011
Table 45: Pontine Glioma Trial Snapshots - 2010
Table 46: Pontine Glioma Trial Snapshots - 2010
Table 47: Pontine Glioma Trial Snapshots - 2010

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll